newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

  • bioAffinity Technologies recorded a record number of CyPath Lung tests in October 2026, marking the highest monthly testing volume for the company.
  • October 2026 testing volume totaled 235 tests, representing a 29% increase compared to October 2025.
  • October's testing volume equated to approximately 45% of all tests performed during the third quarter of 2026.
  • Growth in test utilization was driven by both established physicians & newly ordering doctors.
  • CEO Maria Zannes cited expanded sales teams, partnerships with patient advocacy organizations, & R&D advances for asthma & COPD as key growth drivers.
  • CyPath Lung is a noninvasive Laboratory Developed Test (LDT) that uses flow cytometry & proprietary AI to analyze sputum cell populations.
  • Clinical trials showed the test achieved 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value in high-risk patients with small indeterminate lung nodules.
  • The company continues to advance its commercial strategy through direct physician engagement, distribution relationships, & government healthcare system opportunities.